去甲肾上腺素与肾上腺素用于心脏骤停后休克血流动力学支持的系统评价
该系统评价检索PubMed、Cochrane Library和CINAHL 2000年至2022年文献,比较去甲肾上腺素与肾上腺素作为主要升压药支持在成人心脏骤停后休克或心源性休克伴可提取心脏骤停后数据患者中的效果。数据库检索返回2646项研究,最终纳入2项研究共853名参与者。因产出低,原计划的Meta分析被推迟。两项研究中肾上腺素组院内死亡粗发生率均数值上高于去甲肾上腺素组,但仅一项有统计学显著性;院内死亡率的偏倚风险为中至重度。其他结局在两项研究报告方式不同,使直接比较受限。
要点
- 纳入2项研究共853名心脏骤停后休克成人,比较去甲肾上腺素与肾上腺素作为主要升压药支持。
- 院内死亡粗发生率肾上腺素组在两项研究中均数值上高于去甲肾上腺素组,但仅一项达统计学显著。
- 因研究产出低,原计划的Meta分析被推迟,未进行合并效应量估计。
- 院内死亡率的偏倚风险为中至重度。
- 心脏骤停后休克中死亡率和血流动力学结局最佳的升压药仍不明确,随机研究至关重要。
适用人群与场景
- 成人心脏骤停后休克患者,或心源性休克且可提取心脏骤停后数据的成人。
- 纳入研究类型为前瞻性、回顾性或已发表摘要。
研究设计与关键结果
- 研究设计:系统评价与Meta分析(Meta分析因产出低被推迟),检索PubMed、Cochrane Library和CINAHL 2000年至2022年,数据库检索返回2646项研究。
- 纳入2项研究共853名参与者,比较去甲肾上腺素与肾上腺素作为主要升压药支持。
- 院内死亡粗发生率:肾上腺素组在两项研究中均数值上高于去甲肾上腺素组,但仅一项有统计学显著性。
- 院内死亡率的偏倚风险为中至重度。
- 其他结局(心律失常或难治性休克发生率)在两项研究报告方式不同,使直接比较受限。
证据类型、等级与局限
- 证据类型:系统评价(Meta分析被推迟,未合并效应量)。
- 院内死亡率的偏倚风险为中至重度。
- 局限:原计划的Meta分析因产出低被推迟;其他结局在两项研究报告方式不同,使直接比较受限。
对床旁实践的改变
- 心脏骤停后休克中死亡率和血流动力学结局最佳的升压药仍不明确,作者认为随机研究至关重要以弥补这一空白。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The preferred vasopressor in post-cardiac arrest shock has not been established with robust clinical outcomes data. Our goal was to perform a systematic review and meta-analysis comparing rates of in-hospital mortality, refractory shock, and hemodynamic parameters in post-cardiac arrest patients who received either norepinephrine or epinephrine as primary vasopressor support.
METHODS: We conducted a search of PubMed, Cochrane Library, and CINAHL from 2000 to 2022. Included studies were prospective, retrospective, or published abstracts comparing norepinephrine and epinephrine in adults with post-cardiac arrest shock or with cardiogenic shock and extractable post-cardiac arrest data. The primary outcome of interest was in-hospital mortality. Other outcomes included incidence of arrhythmias or refractory shock.
RESULTS: The database search returned 2646 studies. Two studies involving 853 participants were included in the systematic review. The proposed meta-analysis was deferred due to low yield. Crude incidence of in-hospital mortality was numerically higher in the epinephrine group compared with norepinephrine in both studies, but only statistically significant in one. Risk of bias was moderate to severe for in-hospital mortality. Additional outcomes were reported differently between studies, minimizing direct comparison.
CONCLUSION: The vasopressor with the best mortality and hemodynamic outcomes in post-cardiac arrest shock remains unclear. Randomized studies are crucial to remedy this.
参考来源
- Lawson CK, Faine BA, Rech MA, et al. Norepinephrine versus epinephrine for hemodynamic support in post-cardiac arrest shock: A systematic review. Am J Emerg Med. 2023. PMID: 38150986. doi:10.1016/j.ajem.2023.12.031
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。